Ingrezza

Active Ingredient(s): Valbenazine
FDA Approved: * April 11, 2017
Pharm Company: * NEUROCRINE BIOSCIENCES INC
Category: Neurological Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Ingrezza Overview

Valbenazine, sold under the trade name Ingrezza, is a medication use to treat tardive dyskinesia.[1] It is being studied for Tourette's syndrome.[2][3] It acts as a vesicular monoamine transporter 2 (VMAT2) inhibitor.[4] Contents 1 Contraindications 2 Adverse effects 3 Pharmacology 3.1 Mechanism of action 4 Society and culture 4.1 Commercial aspects 4.2 Intellectual property 4.3 Names 5 See also 6 References Contraindications There are no contraindications.[5] Adverse effe...

Read more Ingrezza Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Valbenazine

Recent Ingrezza Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Valbenazine
  • Capsule: 40mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Valbenazine or a similar ingredient: (1 result)